• To understand the aetiology and key features of the most common forms of amyloidosis
• To recognise the symptoms and signs that should prompt consideration of amyloidosis as a cause of cardiovascular symptoms

Speakers:

Professor Marianna Fontana Deputy Clinical and Research Lead
Dr Yousuf Razvi Clinical Research Fellow
Dr Dorota Rowczenio Head of Genetic Service
Angelique Smit Lead Clinical and Research Nurse
Professor Ashu Wechalekar Laboratory Director and Consultant Haematologist
Dr Carol Whelan Consultant Cardiologist

• To understand the imaging techniques used to diagnose and monitor cardiac amyloidosis, and the key features seen on these studies
• To know all the information and test results that should be included in a referral for a patient suspected of having cardiac amyloidosis
• To understand the role of genetic testing, immunohistochemistry and proteomics in the diagnostic pathway

Speakers:

Professor Marianna Fontana Deputy Clinical and Research Lead
Janet Gilbertson Head of Histology/Proteomic Service and Laboratory Manager
Professor Julian Gillmore NAC Research Lead
David Hutt Lead Nuclear Medicine Technologist
Dr Ana Martínez-Naharro Consultant Cardiologist
Dr Dorota Rowczenio Head of Genetic Service
Angelique Smit Lead Clinical and Research Nurse

• To recognise the signs and symptoms of transthyretin (ATTR) and light-chain (AL) amyloidosis
• To understand which patients should be considered at risk of potentially having amyloidosis, and in whom these red flag symptoms should be assessed

Speakers:

Dr Josephine Mansell Clinical Research Fellow
Angelique Smit Lead Clinical and Research Nurse

• To understand the prevalence of coexisting cardiovascular and kidney disease
• To provide guidance on detecting cardiovascular or kidney disease, and when to refer such patients for specialist care
• To describe the similarities and differences between guidelines on the management of cardiovascular and kidney disease
• To discuss the role of pharmacological treatment options in reducing both cardiovascular and renal risk

Speakers

Dr Jemima Scott NIHR Doctoral Research Fellow and Specialty Trainee in renal medicine, University of Bristol and North Bristol NHS Trust
Professor Chris Gale Professor of Cardiovascular Medicine and Honorary Consultant Cardiologist, University of Leeds and Leeds Teaching Hospitals NHS Trust

Learning module instructions

This BJC TV Learning module has a recommended award of 1 CPD credit for completion (1 hour of learning).
Completion requires a score of at least 80%. If less time is spent learning, then you should claim a reduced credit value.
After you have successfully completed the test you will be able to download your certificate.

References:

1. Entresto (sacubitril/valsartan) Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/15041/smpc (accessed February 2025)
2. Eplerenone Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/3666/smpc (accessed February 2025)
3. NICE. Cardiovascular disease: risk assessment and reduction, including lipid modification [NG238]. December 2023. Available at: https://www.nice.org.uk/guidance/ng238/chapter/Recommendations (accessed February 2025)
4. NICE. Chronic kidney dissease: Scenario: Management of chronic kidney disease. September 2024. Available at: https://cks.nice.org.uk/topics/chronic-kidney-disease/management/management-of-chronic-kidney-disease/ (accessed February 2025)
5. Saeed D et al. Cureus. 2023;15:e51362
6. Song JH et al. BMC Nephrology. 2023;24:289

• Understand secondary prevention measures to implement to reduce the risk of further events in patients with established disease
• Obtain an overview of the pertinent lifestyle and medical intervention strategies available to improve outcomes
• Recognise the importance of personalised approaches to treatment to improve engagement and adherence
• Understand engaging with older patients around technology and tools they can use to maximise these resources

Speakers

Gayle Campbell Lead Heart Failure Pharmacist, Guy’s and St Thomas’ NHS Foundation Trust
Professor Pardeep Jhund Professor of Cardiology and Epidemiology and Honorary Consultant Cardiologist, University of Glasgow

Learning module instructions

This BJC learning module has a recommended award of 1 CPD credit for completion (1 hour of learning). Completion requires a score of at least 75%. If less time is spent learning then you should claim a reduced credit value. After you have successfully completed the test you will be able to download your certificate.

References

1. McDonagh TA et al. Eur Heart J. 2021;42:3599–3726
2. Mebazaa A et al. Lancet. 2022;400:1938–1952
3. NICE. Chronic heart failure in adults: diagnosis and management. 2018. Available at: https://www.nice.org.uk/guidance/ng106/resources/chronic-heart-failure-in-adults-diagnosis-and-management-pdf-66141541311685 (accessed January 2025)

• Why, how and in whom Lp(a) should be measured
• Management of people with high Lp(a) levels
• The role of Lp(a) in atherosclerotic coronary artery disease
• Future prospects for the treatment of people with high Lp(a) levels

Speakers

Dr Dermot Neely Retired Lipidologist, HEART UK Trustee
Dr Jai Cegla Consultant in Chemical Pathology and Metabolic Medicine, Imperial College Healthcare NHS Trust

Learning module instructions

This BJC TV Learning module has a recommended award of 1 CPD credit for completion (1 hour of learning).
Completion requires a score of at least 80%. If less time is spent learning, then you should claim a reduced credit value.
After you have successfully completed the test you will be able to download your certificate.

Click here to view a podcast summary of the video discussion.

References:

1. Cegla J et al. Atherosclerosis 2019;291:62–70
2. Cegla J et al. Ann Clin Biochem 2021;58:16–21
3. Lp(a) Clinical Guidance (2023). Lp(a) risk calculator. Available at: https://www.lpaclinicalguidance.com/ (accessed December 2024)
4. National Clinical Guideline for stroke for the United Kingdom and Ireland (2023 edition). Available at: https://www.strokeguideline.org/app/uploads/2023/04/National-Clinical-Guideline-for-Stroke-2023.pdf (accessed December 2024)

Speakers

Alison Pottle Consultant Nurse in Cardiology, Harefield Hospital, UK
Jai Cegla Consultant in Chemical Pathology and Metabolic Medicine, Imperial College Healthcare NHS Trust, UK 

Learning objectives

• To discuss the available tools and potential barriers to screening for FH

• To provide an overview of the recent advances in treatment for dyslipidaemia

• To discuss the role of lipid apheresis in treating people with homozygous FH

• To outline key discussion points to raise with people with dyslipidaemia

Learning module instructions

This BJC TV Learning module has a recommended award of 1 CPD credit for completion (1 hour of learning).
Completion requires a score of at least 80%. If less time is spent learning, then you should claim a reduced credit value.
After you have successfully completed the test you will be able to download your certificate.

References

1. NICE (2019) Familial hypercholesterolaemia: identification and management [CG71]. Available at: https://www.nice.org.uk/guidance/cg71 (accessed August 2024)
   
   
2. Morrell J. Br J Cardiol 2008;15:79–81.
   
   
3. Public Health England (2018) Familial Hypercholesterolaemia – Implementing a systems approach to detection and management. Available at: https://assets.publishing.service.gov.uk/media/5b646bbced915d37793abcda/familial_hypercholesterolaemia_implementation_guide.pdf (accessed August 2024).
   
   
4. Benn M et al. Eur Heart J. 2016;37:1384–1394.
   
   
5. Mach F et al. Eur Heart J. 2020;41:111–188.